Interview sales

Quote

Anonymous

Guest
I have an interview with AMS, calling on OBGYN doctors this week, Just curious as to the job, compensation, how you are dealing with the litigation, etc. Any one care to provide me some insight? Thanks!
 






Anonymous said:
I have an interview with AMS, calling on OBGYN doctors this week, Just curious as to the job, compensation, how you are dealing with the litigation, etc. Any one care to provide me some insight? Thanks!
Click to expand...

60k, very little commission, company car. Litigation? You bet every day on every call in every case. Sunshine act hell. Otherwise its great.
 


















Anonymous said:
Big Pharma without the opportunity for big money. A pretender company.
Click to expand...

$60k., lots of overnights, chasing cases, no longer the market-leader that they want to be.....your buddy physicians will have to fight for your cases (which they aren't going to do) and get your product on the shelf........think of it as get a denial letter for a prescription and having to go through the "three-step denial letter / appeal process" or a prior-autho for every cases....ugh. Unless you where fired from your last gig, don't try it.....
 












Endo Health Solutions Inc. ENDP +1.09% said its fourth-quarter loss widened after the drug maker warned of a significant write down and high litigation expenses earlier this month.

Endo said previously that it anticipated a $495 million write down related to the purchase of its urology-product unit American Medical Systems Holdings Inc. in 2011, as well as a charge of $316 million to increase it product liability reserve in response to vaginal mesh lawsuits.

The company also gave a weak 2014 earnings outlook, expecting adjusted earnings of $3.40 to $3.65 a share, below the $4.01 a share expected by analysts polled by Thomson Reuters. Endo expects 2014 revenue of $2.5 billion to $2.62 billion, bracketing the $2.59 billion expected by analysts.

Endo's branded-pharmaceutical revenue has declined in recent quarters as its top seller, the after-shingles pain-relief patch Lidoderm, lost market exclusivity last year.

Endo Health reported a loss of $775.9 million, or $6.74 a share, versus a year-earlier loss of $716.3 million, or $6.35 cents, a year earlier. Earlier this month, Endo predicted its reported earnings would be materially below previous expectations of 95 cents to $1.10 a share.

Excluding items such as amortization, impairment and other restructuring costs, adjusted earnings fell to 96 cents a share from of $1.62. Revenue fell 22% to $584.9 million.

Analysts polled by Thomson Reuters had most recently forecast earnings of 93 cents a share on revenue of $621 million.

Operating income widened to a loss of $732.5 million from a year-earlier loss of $704.3 million.

Lidoderm sales plummeted 87% to $36.4 million while Opana ER sales dropped 14% to $53.7 million. The company agreed to pay $193 million earlier this month to settle allegations that it market Lidoderm for uses not approved by regulatory authorities.

Shares closed Thursday at $81.49 and were inactive premarket. The stock has soared in the past 12 months
 






Anonymous said:
Endo Health Solutions Inc. ENDP +1.09% said its fourth-quarter loss widened after the drug maker warned of a significant write down and high litigation expenses earlier this month.

Endo said previously that it anticipated a $495 million write down related to the purchase of its urology-product unit American Medical Systems Holdings Inc. in 2011, as well as a charge of $316 million to increase it product liability reserve in response to vaginal mesh lawsuits.

The company also gave a weak 2014 earnings outlook, expecting adjusted earnings of $3.40 to $3.65 a share, below the $4.01 a share expected by analysts polled by Thomson Reuters. Endo expects 2014 revenue of $2.5 billion to $2.62 billion, bracketing the $2.59 billion expected by analysts.

Endo's branded-pharmaceutical revenue has declined in recent quarters as its top seller, the after-shingles pain-relief patch Lidoderm, lost market exclusivity last year.

Endo Health reported a loss of $775.9 million, or $6.74 a share, versus a year-earlier loss of $716.3 million, or $6.35 cents, a year earlier. Earlier this month, Endo predicted its reported earnings would be materially below previous expectations of 95 cents to $1.10 a share.

Excluding items such as amortization, impairment and other restructuring costs, adjusted earnings fell to 96 cents a share from of $1.62. Revenue fell 22% to $584.9 million.

Analysts polled by Thomson Reuters had most recently forecast earnings of 93 cents a share on revenue of $621 million.

Operating income widened to a loss of $732.5 million from a year-earlier loss of $704.3 million.

Lidoderm sales plummeted 87% to $36.4 million while Opana ER sales dropped 14% to $53.7 million. The company agreed to pay $193 million earlier this month to settle allegations that it market Lidoderm for uses not approved by regulatory authorities.

Shares closed Thursday at $81.49 and were inactive premarket. The stock has soared in the past 12 months
Click to expand...


AMS is a pimple on the rear of ENDO. Which is why the endo is nearo. But we will be the first to feel the brunt of the layoffs. A lotta fat to trim.
 




































Anonymous said:
No pun intended. Or was it intended?

Now that the vast majority of mesh lawsuits are settled - hold onto your hats. I would bet you we are sold off by July. Not just PH - the whole AMS ship will be sold, MH, FH and PH.
Click to expand...

There is still some risk in aquiring AMS. My guess is that no one wants any part of WH. Mens is a cash cow and PH is and always has been a loser. I dont think Camille would agree to a deal that spins out our only jewel in MH. PH could be sold to one of the larger mobiles and WH shut down. Tonka would be filled with temporary asians used to manufacture and fda paper shufflers that make sure the rat traps are picked up and that the paperwork is filed.
 






Anonymous said:
There is still some risk in aquiring AMS. My guess is that no one wants any part of WH. Mens is a cash cow and PH is and always has been a loser. I dont think Camille would agree to a deal that spins out our only jewel in MH. PH could be sold to one of the larger mobiles and WH shut down. Tonka would be filled with temporary asians used to manufacture and fda paper shufflers that make sure the rat traps are picked up and that the paperwork is filed.
Click to expand...

AMS is for sale this is accurate. I agree that what ever is left Minnesota is a ghost town.
 












Anonymous said:
$60k., lots of overnights, chasing cases, no longer the market-leader that they want to be.....your buddy physicians will have to fight for your cases (which they aren't going to do) and get your product on the shelf........think of it as get a denial letter for a prescription and having to go through the "three-step denial letter / appeal process" or a prior-autho for every cases....ugh. Unless you where fired from your last gig, don't try it.....
Click to expand...

Amen.
 
























Top Bottom
Back
Quote